ESMO ADVANCED COURSE PROGRAMME

PRECISION ONCOLOGY IN ONCOGENE-ADICTED NSCLC: RARE EGFR, KRAS, BRAF, RET

Barcelona, Spain
1-2 September 2023

CO-CHAIRS
Sabina Berezowska, Switzerland
Jürgen Wolf, Germany

SPEAKERS
Keith Kerr, United Kingdom
Anna Kron, Germany
Sonja Loges, Germany
Fernando López-Ríos, Spain
Umberto Malapelle, Italy
Sanjay Popat, United Kingdom
Noemi Reguart, Spain
Albrecht Stenzinger, Germany

LEARNING OBJECTIVES

- To understand the biology of specific oncogene addicted NSCLC and the rational for targeted treatment
- To review the targeted treatment strategies, including current approvals and ongoing trials, in patients with oncogene addicted NSCLC
- To learn about the best current practice regarding testing methodology and get an outlook on future developments
- To improve interdisciplinary collaboration between oncology and pathology by understanding individual challenges in testing and treatment
- To understand health economical aspects of targeted treatment in NSCLC

Friday, 1 September 2023

09:00-09:10 Welcome and introduction
10’ Welcome and Learning Objectives Introduction
Sabina Berezowska, CH and Sonja Loges, DE

09:10-10:55 Session 1 – Molecular target / Family of targets - Rare EGFR
Chairs: Noemi Reguart, ES and Albrecht Stenzinger, DE

15’ Biology of the target / biomarker (function and roles in normal and tumour tissue homeostasis)
Umberto Malapelle, IT
5’ Q&A

20’ Update on the clinical efficacy of approved targeted agents: formal indications, efficacy and toxicity
Sonja Loges, DE
5’ Q&A

20’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Umberto Malapelle, IT
10’ Q&A
20' A clinicopathological case presented and discussed by a Molecular Tumour Board
   *Sonja Loges, DE*

10' Q&A

10:55-11:25 *Coffee break*

11:25-13:10 *Session 2 – Molecular target / Family of targets - KRAS*
   Chairs: *Sonja Loges, DE* and *Fernando López-Ríos, ES*

15' Biology of the target / biomarker (function and roles in normal and tumour tissue homeostasis)
   *Sabina Berezowska, CH*

5' Q&A

20' Update on the clinical efficacy of approved targeted agents: formal indications, efficacy and toxicity
   *Sanjay Popat, UK*

5' Q&A

20' Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
   *Albrecht Stenzinger, DE*

10' Q&A

20' A clinicopathological case presented and discussed by a Molecular Tumour Board
   *Sanjay Popat, UK*

10' Q&A

13:10-14:10 *Lunch*

14:10-15:55 *Session 3 – Molecular target / Family of targets - BRAF*
   Chairs: *Sabina Berezowska, CH* and *Sanjay Popat, UK*

15' Biology of the target / biomarker (function and roles in normal and tumour tissue homeostasis)
   *Keith Kerr, UK*

5' Q&A

20' Update on the clinical efficacy of approved targeted agents: formal indications, efficacy and toxicity
   *Noemi Reguant, ES*

5' Q&A

20' Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
   *Keith Kerr, UK*

10' Q&A

20' A clinicopathological case presented and discussed by a Molecular Tumour Board
   *Noemi Reguant, ES*

10' Q&A

15:55-16:25 *Coffee break*

19:30 *Networking Dinner*
Saturday, 2 September 2023

09:00-09:40  **Session 4 – Precision oncology from the perspective of health economics**
Chairs: Keith Kerr, UK and Jürgen Wolf, DE

30’  Value / health economics of testing and targeting (incl. MCBS, ESCAT actionability, RWD)
*Anna Kron, DE*
10’  Discussion

09:40-11:55  **Session 5 – Molecular target / Family of targets - RET**
Chairs: Umberto Malapelle, IT and Sanjay Popat, UK

15’  Biology of the target / biomarker (function and roles in normal and tumour tissue homeostasis)
*Fernando López-Rios, ES*
5’  Q&A

20’  Update on the clinical efficacy of approved targeted agents: formal indications, efficacy and toxicity
*Jürgen Wolf, DE*
5’  Q&A

10:25-10:55  **Coffee break**

20’  Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
*Fernando López-Rios, ES*
10’  Q&A

20’  A clinicopathological case presented and discussed by a Molecular Tumour Board
*Jürgen Wolf, DE*
10’  Q&A

11:55-12:05  **Synthesis and wrap-up**
*Sabina Berezowska, CH and Jürgen Wolf, DE*

12:05-13:05  **Lunch**